Myelodysplastic syndrome overview

Revision as of 20:52, 3 December 2015 by Nawal Muazam (talk | contribs)
Jump to navigation Jump to search

Myelodysplastic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelodysplastic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelodysplastic syndrome overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelodysplastic syndrome overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelodysplastic syndrome overview

CDC on Myelodysplastic syndrome overview

Myelodysplastic syndrome overview in the news

Blogs on Myelodysplastic syndrome overview

Directions to Hospitals Treating Myelodysplastic syndrome

Risk calculators and risk factors for Myelodysplastic syndrome overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]

Overview

The myelodysplastic syndromes (MDS, formerly known as "preleukemia") are a diverse collection of hematological conditions united by ineffective production of blood cells and varying risks of transformation to acute myelogenous leukemia. Anemia requiring chronic blood transfusion is frequently present. Although not truly malignant, MDS is nevertheless classified within the haematological neoplasms. Since the early 20th century it began to be recognized that some people with acute myelogenous leukemia had a preceding period of anemia and abnormal blood cell production. These conditions were lumped with other diseases under the term "refractory anemia". The first description of "preleukemia" as a specific entity was published in 1953 by Block et al. The early identification, characterization and classification of this disorder were problematical, and the syndrome went by many names until the 1976 FAB classification was published and popularized the term MDS.

Historical Perspective

Myelodysplastic syndrome was first described in 1900 by Leube.[1]

Classification

Pathophysiology

Causes

Differentiating Myelodysplastic syndrome from other Diseases

Epidemiology and Demographics

The incidence of myelodysplastic syndrome is approximately 4.4 to 4.6 cases per 100,000 individuals in the United States.[2] Myelodysplastic syndrome commonly affects older patients.[2] Males are more commonly affected with myelodysplastic syndrome than females.[2] Myelodysplastic syndrome usually affects individuals of the Caucasian race.[2]

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and symptoms

Symptoms of myelodysplastic syndrome include bleeding, easy bruising, and fatigue.[2]

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical therapy

Surgery

Prevention

References

  1. Nimer, S. D. (2008). "Myelodysplastic syndromes". Blood. 111 (10): 4841–4851. doi:10.1182/blood-2007-08-078139. ISSN 0006-4971.
  2. 2.0 2.1 2.2 2.3 2.4 Incidence and mortality of myelodysplastic syndromes. National Cancer Institute 2015. http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq#link/_291_toc. Accessed on December 3, 2015


Template:WikiDoc Sources